Prothena recently presented results from a Phase 1b clinical trial investigating a new antibody therapy for the treatment of Parkinson’s disease at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Vienna, Austria. The trial was an ascending dose study of a novel antibody known as PRX002/RG7935.
Hepatitis B and C patients are more likely to develop Parkinson’s disease (PD) than people without hepatitis, according to a British study, “Viral hepatitis and Parkinson disease,” that appeared in the journal Neurology. Hepatitis is a chronic liver inflammation usually triggered by viral infection. Hepatitis B and C are spread…
Australia’s Prana Biotechnology will demonstrate pre-clinical results of PBT434 as a novel therapeutic strategy for managing Parkinson’s disease during the 13th International Conference on Alzheimer’s & Parkinson’s Diseases, set for March 29-April 2 in Vienna. The results will be presented in a poster, “PBT434 prevents neuronal loss, motor…
Treating Parkinson’s disease with CVT-301 — an investigational, inhaled levodopa — causes no changes in lung function, according to results of two clinical trials led by Acorda Therapeutics of Ardsley, New York. Acorda is developing CVT-301 to treat “off” episodes in Parkinson’s patients who are taking oral carbidopa/levodopa. The inhaled formulation delivers a precise…
Results of the Cantabio Pharmaceuticals’ therapeutic program targeting the protein DJ-1 as a new therapeutic avenue for Parkinson’s disease will be presented at the 13th International Conference on Alzheimer’s and Parkinson’s Disease, being held in Vienna on March 29-April 2. The presentation, to be delivered by Cantabio’s CEO…
The Journal of Parkinson’s Disease has organized a special issue for Parkinson’s Awareness Month, to mark the 200th anniversary of James Parkinson’s first account of the disease that would one day bear his name. This is a special issue of the Journal of Parkinson’s Disease. (Photo…
Increasing treatment success in Parkinson’s requires a change in the way researchers and doctors view and approach this disease, experts wrote in two recent studies. “The time has come to ask what we should be doing differently,” Alberto Espay, MD, senior author of both studies, said in a news…
Flexilev microtablets containing both levodopa/carbidopa, used with an automatic dose dispenser, seemed to improve self-reported symptom control in some patients with Parkinson’s disease, according to a first report of the treatment’s real-life use. The study, “First clinical experience with levodopa/carbidopa microtablets in Parkinson’s disease,” also noted that most patients…
Contrary to current scientific thought, tracking the activity of a protein called dopamine transporter (DAT) may not reflect the loss of dopamine neurons in an area of the brain called the substantia nigra (one of the most affected regions in patients with Parkinson’s disease). These findings were published in the…
The U.S. Food and Drug Administration (FDA) has approved Xadago (safinamide) as an add-on therapy to increase the effectiveness of levodopa/carbidopa in Parkinson’s disease. Xadago limits the number of “off” episodes, or increases in symptoms, among patients on levodopa/carbidopa, clinical trials have shown. “Parkinson’s is a relentless disease without a cure,” Eric Bastings,…
Get regular updates to your inbox.
